The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
FDA clears FT538, the first CRISPR-edited, iPSC-derived cell therapy, for investigation as a new drug in AML and MM
On May 20, 2020, the U.S. Food & Drug Administration (FDA) cleared FT538, the first CRISPR-edited, induced pluripotent stem cell (iPSC)-derived cell therapy, for clinical investigation as a new monotherapy for patients with acute myeloid leukemia (AML) and as a combination therapy with daratumumab, a CD38-directed monoclonal antibody therapy, for the treatment of multiple myeloma (MM).1
Key features1
FT538
- An off-the-shelf natural killer (NK) cell cancer immunotherapy, derived from a clonal master iPSC line
- Engineered with three functional components to enhance innate immunity:
- A novel high-affinity, non-cleavable CD16 Fc receptor that improves antibody-dependent cellular cytotoxicity by enhancing NK cells to recognize, bind, and kill antibody-coated cancer cells
- An IL-15/IL-15 receptor complex that promotes NK cell survival and persistence, as well as inducing trans-activation of endogenous NK cells and CD8 T cells
- Elimination of CD38 expression, which enhances innate effector function, including granzyme and perforin levels, and resistance to oxidative stress, as well as preventing anti-CD38 antibody-mediated NK cell death
Study Design1,2
- Phase I, multi-center, dose-escalation trial to determine the maximum tolerated dose (MTD) of three once-weekly doses of FT538 in up to 105 adult patients
- Four dose cohorts of 100M cells, 300M cells, 900M cells, or 1.5B cells per dose
- Designed to assess two treatment regimens:
- As a monotherapy in patients with relapsed/refractory AML
- In combination with daratumumab in patients with relapsed/refractory MM who have failed at least two lines of therapy
- There is also potential for initiation of a third treatment regimen in combination with elotuzumab, an FDA-approved anti-SLAMF7 monoclonal antibody, in patients with relapsed/refractory MM who have failed at least two lines of therapy
The therapy aims to provide a robust population of NK cells that are resistant to depletion when used in combination with anti-CD38 antibodies and thus improve outcomes for patients with MM and AML.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?